Dr Robert Grundel
Guest ContributorJanuary 25, 2010
Dr Robert Grundel has been appointed VP R&D for Amorfix Life Sciences, a Toronto-based developer of treatments and diagnostics for brain-wasting diseases and cancer. Grundel comes to Amorfix with considerable experience in the pharmaceutical industry. Over the past 25 years he has held executive positions with Heat Biologics Inc, Miami Beach FL, Elusys Therapeutics Inc, Pine Brook NJ, Arius Research Inc, Toronto (purchased by Roche), Chiron Corp, Emeryville CA (purchased by Novartis International AG), Bayer Corp, Leverkusen Germany and Boehringer Ingelheim Pharmaceuticals Inc, Ingelheim Germany. Over his career, Grundel has focused on new product development specializing in therapeutic monoclonal antibodies and vaccines….
The Digital Media and Wireless Association of British Columb
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.